Answer
Trabectedin requires a thorough cardiac assessment, including left ventricular ejection fraction measurement by echocardiogram or multigated acquisition scan (MUGA), before treatment and every 2–3 months until discontinuation, alongside monitoring for cardiac adverse events or myocardial dysfunction.
Sources for this answer
- Yondelis 0.25 mg powder for concentrate for solution for infusionImmedica · emc · SmPC §4.4 Special warnings and precautions for use · Version 23Document updated
Sources checked